Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Galena Biopharma Shares Soared

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Galena Biopharma (NASDAQ: GALE  ) advanced as much as 20% after the company focused on developing cancer therapies announced the acquisition of Mills Pharmaceuticals and received a price target upgrade from Roth Capital.

So what: According a Galena press release that did not mention any financial terms, the acquisition of Mills Pharmaceuticals gives Galena worldwide rights to GALE-401, a patented, controlled release formulation of anagrelide. Galena expects to pursue an expedited regulatory pathway for FDA approval of GALE-401 as a treatment for essential thrombocythemia, a rare bone marrow disease. Galena estimates the experimental therapy has peak market potential of $200 million. On the heels of this news, Roth Capital boosted its price target on Galena to $11 from $7.

Now what: If Galena can get GALE-401 on an expedited review path this will likely be a smart purchase, although we can never tell for certain without financial terms of the deal being disclosed. Ultimately, Galena shares are roaring higher at just the right time -- cancer immunotherapy treatments are a hot issue among investors at the moment, and the mecca of all health-care events, the JPMorgan Healthcare Conference, is going on this week. I would, however, still recommend exercising caution here with Galena, as many of its major catalysts, specifically as they relate to NeuVax, are still years away.

Can this top stock actually outperform Galena in 2014?
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (2) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 13, 2014, at 7:14 PM, Zankudo wrote:

    ever hear of abstal…already rolling…it's not a one pony show…

  • Report this Comment On January 13, 2014, at 11:02 PM, bigmac7406 wrote:

    Gale is up approximately 350% since October. Exercise too much caution and you could miss this wonderful opportunity.

    The catalyst that can make you rich is not years away. The primary completion date for Phase 3 NeuVax trials is 15 months away. Source

    Phase 3 NeuVax trials primary completion and FDA decision likely May 2015. Gale's share price could likely skyrocket as did Intercept this week.

    Between now and May 2015 there are many catalyst that will likely continue to push the price up. These include in the short term:

    - Increased Institutional Holding

    - Abstral Sales Potential

    - Valuation

    - Gale will announce full enrollment of Phase 2 clinical Trials of Folate Binding Protein for ovarian cancer.

    - The 70 events on Phase 3 NeuVax will be reached. Interim reports on NeuVax are good.

    - NeuVax Phase 2b (NeuVax + Herceptin) will yield results comparable to Phase 2.

    - Gale will report sales data for Q4 of 2013.

    This is "The One" you have been looking for.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2793242, ~/Articles/ArticleHandler.aspx, 8/27/2015 3:50:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,533.34 247.83 1.52%
S&P 500 1,969.43 28.92 1.49%
NASD 4,778.85 81.31 1.73%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 3:34 PM
GALE $1.49 Down +0.00 +0.00%
Galena Biopharma,… CAPS Rating: *